Chemotherapy as first treatment for primary malignant non-Hodgkin's lymphoma of the central nervous system preliminary data

Amerigo Boiardi, Antonio Silvani, Sergio Valentini, Andrea Salmaggi, Antonio Allegranza, Giovanni Broggi

Research output: Contribution to journalArticle

Abstract

Non-Hodgkin's lymphoma of the central nervous system (NHL-CNS) is thought to account for about 1 % of primary brain tumours. Radiation therapy has mainly been applied to treat cerebral lymphoma, but the low cure rate and the lack of enduring response have stimulated the search for alternatives. With the aim of postponing radiotherapy as long as possible, we tested the efficacy of a M-BACOD schedule administered immediately after histological diagnosis in 14 patients. After two M-BACOD courses 10 (71%) patients displayed an objective response (i.e. were apparently tumour-free when examined by CT). In 6 (60%) M-BACOD-responsive patients, radiotherapy was delayed for 5 months (without recurrences after a follow-up ranging from 9 to 18 months). Moreover, in 3 M-BACOD-responsive patients, no recurrence took place (even without radiotherapy) after a follow-up of 6-12 months. We conclude that radiation can be postponed after chemotherapy or delayed until tumor recurrence.

Original languageEnglish
Pages (from-to)96-100
Number of pages5
JournalJournal of Neurology
Volume241
Issue number2
DOIs
Publication statusPublished - Feb 1993

    Fingerprint

Keywords

  • Cerebral non-Hodgkin's lymphoma
  • Chemotherapy
  • Highdose methotrexate

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this